New Recruiting Trial: A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
WHY IT MATTERS
This trial is now recruiting patients undergoing haploidentical hematopoietic stem cell transplant at City of Hope Medical Center — CMV reactivation is a major cause of complications and death after this procedure, making this preventive vaccine potentially life-changing for transplant recipients.
Researchers are testing a new vaccine called CMV-MVA Triplex Vaccine to help patients who are receiving a special type of bone marrow transplant called haploidentical stem cell transplant. Cytomegalovirus (CMV) is a common virus that can cause serious problems after this type of transplant. This vaccine is designed to strengthen the body's immune system against CMV and prevent the virus from spreading in the blood.
NCT ID: NCT07020533 Title: A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Status: RECRUITING Phase: PHASE1 Sponsor: City of Hope Medical Center Start date: 2026-05-08 URL: https://clinicaltrials.gov/study/NCT07020533 Source: UniteRare clinical trials database
ASK YOUR DOCTOR
If you or a loved one is scheduled for haploidentical stem cell transplant, ask your transplant team whether you might be eligible for this trial or if they have information about CMV prevention strategies.